Importantly, this clinical trial was performed in patients having failed chemotherapy and/or immunotherapy, and thus these treatment outcomes may not be applicable to all bladder cancers with FGFR3 mutations. The gene discussed is FGFR3; the disease is urinary bladder carcinoma.